Want to join the conversation?
$ALLE 2Q15 Call: Adjusted EPS of $0.71 increased 16.4% vs. 2Q14, driven primarily from improved operating performance and lower tax rate, partially offset by incremental investments and FX impact. This was the fourth straight quarter with double-digit EPS growth. Raising full-year 2015 adjusted EPS guidance to a range of $2.70-2.80 per share.
Biodefense therapeutics firm $PIP announced an all-stock merger with biotech Altimmune. The respective boards of the two companies unanimously approved the merger.
$YHOO is reporting today after market close. Nobody cares about this stock.